(Q37103050)

English

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

scientific article published on 04 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

chronic myeloid leukemia

0 references

United States of America

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Stacie B. Dusetzina

object named as

Stacie B Dusetzina

3

0 references

Richard A. Larson

object named as

Richard A Larson

2

0 references

Giovanni Martinelli

12

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

Michele Baccarani

6

object named as

Michele Baccarani

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

Dietger Niederwieser

15

object named as

Dietger Niederwieser

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jane F Apperley

4

object named as

Jane F Apperley

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Charles A Schiffer

17

object named as

Charles A Schiffer

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Susanne Saussele

16

object named as

Susanne Saussele

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

François Guilhot

9

object named as

Francois Guilhot

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Francois-Xavier Mahon

11

object named as

Francois-Xavier Mahon

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

8

object named as

Joelle Guilhot

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

author name string

William V Padula

1

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Rudiger Hehlmann

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Ekkehard Eigendorff

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Rudiger Hehlmann

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Jiri Mayer

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Martin C Müller

14

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Richard T Silver

18

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Bengt Simonsson

19

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Rena M Conti

20

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

4 March 2016

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Journal of the National Cancer Institute

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

108

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Chronic myeloid leukemia-transplantation in the tyrosine kinase era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Determining the cost of obesity and its common comorbidities from a commercial claims database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

The ethics of 'fail first': guidelines and practical scenarios for step therapy coverage policies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Deep molecular response in chronic myeloid leukemia: the new goal of therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Is going for cure in chronic myeloid leukemia possible and justifiable?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Costs and cost-effectiveness of hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Pharmaceutical step-therapy interventions: a critical review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

14 September 2017

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

29 September 2017

Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

27 June 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

27 June 2018

High cancer drug prices in the United States: reasons and proposed solutions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

A multinational study of health state preference values associated with chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

3 September 2018

Clinical efficacy of generic imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4948567

20 October 2018

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26944912

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/JNCI/DJW003

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37103050&oldid=2148938295"